Veracyte Announces New Data Published in Journal of Clinical Oncology Suggest the Prosigna Breast Cancer Test’s Genomic Underpinning Drives Prognostic Performance
Veracyte, Inc., (Nasdaq: VCYT) announced today that findings from the first study evaluating the molecular drivers underlying multiple prognostic genomic breast cancer tests were published in the Journal of Clinical Oncology (JCO). Results suggest that the genomic underpinnings of Veracyte’s Prosigna® Breast Cancer Gene Signature Assay, particularly the test’s relative weighting of genes predicting tumor proliferation, may explain the classifier’s previously demonstrated, higher likelihood of predicting long-term risk of recurrence among certain breast cancer patients, compared to other breast cancer tests.
The study compared the commercial forms of four breast cancer recurrence-risk tests: the PAM50-based Prosigna Risk of Recurrence (ROR), the Oncotype DX Risk Score (RS), EndoPredict (EP) and Breast Cancer Index (BCI). It expands upon a previous evaluation of these same tests using an identical dataset, which compared their ability to accurately predict 10-year distant disease recurrence.1 The new study was intended to help determine why these tests commonly generate discordant results and thereby help to inform long-term therapeutic decision-making.
Researchers evaluated 785 patient samples from the TransATAC dataset using each of the four tests and then compared the resulting recurrence risk scores. Their comparisons included the molecular features driving each of the scores, without the clinicopathologic features that are integrated into the final prognostic result for the Prosigna ROR, EP and BCI. All TransATAC samples were derived from the randomized ATAC (Anastrozole, Tamoxifen Alone or in Combination) clinical trial, which involves postmenopausal women with hormone receptor-positive, HER2-negative, early-stage breast cancer who had received five years of endocrine therapy. A genomic test result indicating low risk of distant disease recurrence (i.e., disease recurrence within 10 years) among this population suggests the potential for a patient to safely forego chemotherapy.
“Gene expression assays can help physicians identify which ER+ breast cancer patients can safely avoid chemotherapy, a decision that can have meaningful clinical and quality-of-life implications,” said Matthew Ellis, MBBChir, Ph.D., FRCP, Baylor College of Medicine, and one of the developers of the PAM50 genomic signature. “However, the four most prominent genomic classifiers often provide discordant results. This study is the first to provide a molecular explanation of discordance, which will enhance insights into the respective value of each test, and therefore the most appropriate usage, particularly in determining risk of distant recurrence.”
Study results showed that there was low correlation between the Oncotype DX RS and the Prosigna ROR score, and between the RS and BCI scores. Researchers subsequently determined that genes predicting tumor proliferation (i.e., the rate at which cancer cells divide) accounted for 72.5% of the difference between the RS and Prosigna score and 54.3% of the difference between the RS and BCI scores. Among the four tests, researchers found that the Prosigna ROR score relies most heavily on proliferation-related features, while the RS is determined much more strongly by estrogen-related features. Tumor proliferation is known to be an important and reliable indicator of distant disease recurrence and is indicative of response to chemotherapy.
“Clarity about the relative influence of the proliferation vs. estrogen modules in each of these gene expression assays is important for several reasons, including the fact that this information helps clinicians evaluate the relative benefit of endocrine therapy alone vs. endocrine therapy plus chemotherapy for individual patients,” said Dr. Ellis.
The Prosigna Breast Cancer Prognostic Gene Signature Assay, which is powered by the PAM50 gene signature, uses advanced genomic technology to classify breast cancers based on key biomarkers and the likelihood of cancer recurrence. Outside of the United States, it is also utilized to provide breast cancer intrinsic subtype information. Veracyte acquired the Prosigna test from NanoString Technologies, Inc. in December 2019 as part of its acquisition of the exclusive global diagnostic rights to the nCounter® Analysis System.
“The findings from this study further validate the molecular biology underlying the accuracy of our Prosigna test,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “We are grateful to the study’s investigators, who have provided the breast cancer community with important new data that will undoubtedly help inform treatment decisions for thousands of women.”
Prosigna is a prognostic Breast Cancer Gene Signature assay indicated in female breast cancer patients who have undergone either mastectomy or breast-conserving therapy in conjunction with locoregional treatment consistent with standard of care, either as a prognostic indicator for distant recurrence-free survival at 10 years in post-menopausal women with Hormone Receptor-Positive (HR+), lymph node-negative, Stage I or II breast cancer or lymph node-positive (1–3 positive nodes, or 4 or more positive nodes), Stage II or IIIA breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors. Outside of the U.S., the Prosigna test also provides the intrinsic subtypes of the tumor tissue within three groups, low, intermediate and high by the nCounter technology with high accuracy by decentral performance.
The Prosigna test is FDA 510(k) cleared in the United States for use on the nCounter instrument and is available for use when ordered by a physician. The Prosigna test has received CE Mark, showing that it conforms with European Union regulations, and is available for use by healthcare professionals in the European Union and other countries that recognize the CE Mark, as well as in Canada, Israel, Australia, New Zealand and Hong Kong. The test is covered by Medicare and leading private payers in the United States and is widely covered by government and private payers in the countries where it is available.
Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to Veracyte’s Prosigna® Breast Cancer Gene Signature Assay for use in predicting long-term risk of recurrence among breast cancer patients. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. Examples of forward-looking statements include, among others, statements regarding Veracyte’s belief that its Prosigna “PAM50” molecular classifier helps physicians accurately predict long-term risk of recurrence among breast cancer patients. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: Veracyte’s ability to achieve and maintain Medicare coverage for its tests, the benefits of Veracyte’s tests and the applicability of clinical results to actual outcomes. Factors that may impact these forward-looking statements can be found in Item 1A – “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on February 25, 2020 and in our Quarterly Report on Form 10-Q filed with the SEC on July 30, 2020. A copy of these documents can be found at the Investors section of our website at www.veracyte.com. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.
Veracyte, Afirma, Percepta, Envisia, Prosigna, LymphMark, and the Veracyte logo are trademarks of Veracyte, Inc.
Dr. Ellis was not involved in the analysis, but he does receive income from royalties on PAM50-based diagnostics.
1 Sestak I., Buus R., et. al. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018 Apr 1;4(4):545-553.
Investor and Media Contact:
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Abionic Launches First Covid-19 Severity Test to Triage Patients Quickly and Accurately26.11.2020 07:00:00 EET | Press release
Abionic SA, a Swiss Medtech firm based in Lausanne, has developed the cSOFA score, a tool to assess the severity of Covid-19. The cSOFA score (Covid Sequential Organ Failure Assessment) measures the likelihood of clinical deterioration in Covid-19 patients, enabling triage and assignment to the general ward or intensive care units (ICU) upon admission and during the patients’ hospital stay. A low score allows medical decisions to be made on safely discharging patients from the hospital or moving them from the ICU to the general ward, freeing up much-needed ICU and hospital capacities. In the wake of the Covid-19 pandemic, countries around the globe are faced with increasing occupancy rates in hospitals, particularly in ICUs, and many ICUs at or near capacity. Patient triage, until now, has relied mostly on patient age, a criterion sometimes criticized for being discriminatory. The cSOFA score enables a shift from demographic to medical criteria, taking into account the severity of each
Mavenir and Airtel Demonstrate O-RAN RIC (RAN Intelligent Controller) at Global O-RAN ALLIANCE Plugfest hosted by Airtel in India26.11.2020 06:00:00 EET | Press release
Bharti Airtel (“Airtel”), India’s largest integrated telco, together with Mavenir, demonstrated O-RAN Intelligent Controller (RIC), at the recent Global O-RAN ALLIANCE Plugfest it hosted. The Global Plugfest, which was a first for the India region participation, showcased the growing maturity of the O-RAN ecosystem. The event allowed participants to integrate and validate conformance & interoperability of the solutions implemented based on O-RAN defined architecture & specifications to accelerate readiness of solutions for commercial deployments. The O-RAN Intelligent Controller (RIC) demonstrated by Mavenir and Airtel makes use of advanced machine learning algorithms to optimize network performance. This demonstration showed RIC in action, ingesting configuration data and performance metrics from a demonstration RAN, and iteratively optimizing the configuration parameters to achieve improvement in key performance indicators. The target objective function is configurable by the operato
MEDIROM Healthcare Technologies Inc. Announces Filing of Registration Statement for Proposed Initial Public Offering on NASDAQ25.11.2020 18:00:00 EET | Press release
MEDIROM Healthcare Technologies Inc. (“MEDIROM”), the healthcare company which runs branded relaxation salons in Japan, today announced it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its American Depositary Receipts which represent the common shares of the Company. The number of ADRs to be offered and the price range for the proposed offering have not yet been determined. MEDIROM has applied to list its ADR on Nasdaq Capital Market. Maxim Group LLC is acting as lead manager and representative of the underwriters for the offering. The proposed offering will be made only by means of a prospectus. Once available, a copy of the preliminary prospectus related to the offering may be obtained at the SEC's website at http://www.sec.gov or from the offices of Maxim Group LLC, Attention: Prospectus Department, 405 Lexington Ave Second Floor, New York, NY 10174, telephone: 1-212-
Xinhuanet: Chengdu’s Talent Appeal Spurs the City’s Embrace of the World25.11.2020 17:39:00 EET | Press release
“Chengdu is increasingly attracting skilled talent and entrepreneurs to integrate, put down roots, and start businesses in the city. The city continues to become more appealing, which in turn further promotes its international development,” said Xu Wen, head of Southwestern business at PwC’s Chengdu branch. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201125005704/en/ Xu Wen, head of Southwestern business at PwC’s Chengdu branch, takes a media interview (Photo: Business Wire) In the “City of Opportunity 2020” report released by PwC this year, Chengdu ranked 5th in China, only surpassed by Beijing, Shanghai, Guangzhou, and Shenzhen. Xu sees Chengdu’s great advantage as a “new first-tier” city reflected in the city’s appeal to skilled talent. “With China’s economy undergoing transformation and upgrading, innovation capabilities are becoming more and more important. In this context, cultivating developmental advantages is a c
ViacomCBS to Sell Simon & Schuster to Penguin Random House for $2.175 Billion25.11.2020 17:00:00 EET | Press release
ViacomCBS Inc. (NASDAQ: VIAC, VIACA) today announced it has entered into a definitive agreement to sell the publishing business Simon & Schuster (“Simon & Schuster”) to Penguin Random House LLC (“Penguin Random House”), a wholly owned subsidiary of Bertelsmann SE & Co. KGaA, for $2.175 billion in cash. This divesture follows a strategic review of non-core assets ViacomCBS undertook early in 2020. Proceeds from the transaction will be used to invest in ViacomCBS’s strategic growth priorities, including in streaming, as well as to fund the dividend and pay down debt. This transaction is the outcome of a highly competitive auction that attracted interest from buyers around the world, reflecting Simon & Schuster’s position as one of the world’s best known publishing brands. Simon & Schuster has more than 30 publishing units across adult, children, audio and international. Its portfolio of best-selling authors includes Stephen King, Doris Kearns Goodwin and Jason Reynolds, and it owns a ric
Enhancing the HD-PLC™ Security Functions25.11.2020 17:00:00 EET | Press release
HD-PLC Alliance *1 has started standardization work that will allow the use of enhanced network security functions, with the aim of using High-Definition Power Line Communication technology in the fields of smart grids and distributed power management. HD-PLC™*2 (hereinafter referred to as HD-PLC) technology has already been standardized as IEEE 1901 (Broadband over Power Line Networks for MAC and PHY) by the IEEE Standards Association*3 . This technology is particularly attracting attention in Europe as a communication infrastructure that can be used for distributed power management of energy. Therefore, the current security functions will be enhanced and expanded, including making the technology compatible with strong authentication functions required for use in large-scale networks. Current HD-PLC technology offers extremely high security at the device level, including continuous encrypted communication and authentication between compatible devices. However, for PLC equipment to be
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom